ADC Therapeutics SA
$ 4.39
-0.45%
24 Feb - close price
- Market Cap 546,298,000 USD
- Current Price $ 4.39
- High / Low $ 4.68 / 4.36
- Stock P/E N/A
- Book Value -2.12
- EPS -1.41
- Next Earning Report 2026-03-26
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.24 %
- ROE -7.06 %
- 52 Week High 4.80
- 52 Week Low 1.05
About
ADC Therapeutics SA, a biotechnology company focused on clinical stage oncology, develops Antibody Drug Conjugates (ADC) for patients suffering from hematologic malignancies and solid tumors. The company is headquartered in Epalinges, Switzerland.
Analyst Target Price
$8.00
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-10 | 2025-08-12 | 2025-05-05 | 2025-03-27 | 2024-11-07 | 2024-08-06 | 2024-05-06 | 2024-03-13 | 2023-11-07 | 2023-08-08 | 2023-05-09 | 2023-02-28 |
| Reported EPS | -0.19 | -0.25 | -0.36 | -0.25 | -0.42 | -0.38 | -0.56 | -1.03 | -0.58 | -0.58 | -0.74 | -0.3 |
| Estimated EPS | -0.36 | -0.39 | -0.4143 | -0.43 | -0.38 | -0.46 | -0.56 | -0.5 | -0.63 | -0.46 | -0.67 | -0.29 |
| Surprise | 0.17 | 0.14 | 0.0543 | 0.18 | -0.04 | 0.08 | 0 | -0.53 | 0.05 | -0.12 | -0.07 | -0.01 |
| Surprise Percentage | 47.2222% | 35.8974% | 13.1064% | 41.8605% | -10.5263% | 17.3913% | 0% | -106% | 7.9365% | -26.087% | -10.4478% | -3.4483% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-26 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.32 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ADCT
2026-02-23 21:17:37
ADC Therapeutics (NYSE:ADCT) saw its shares rise by 6.7% to $4.375 on Monday, with analysts largely assigning a "Moderate Buy" rating and an average price target of $7.50. Institutional investors, including Prosight Management and Nantahala Capital Management, have been increasing their stakes in the company. ADC Therapeutics specializes in developing antibody-drug conjugates for hematological malignancies.
2026-02-23 12:36:36
ADC Therapeutics SA has announced that any acquirer in a change of control event will be obligated to continue paying royalties to the healthcare royalty company. This commitment remains in effect until the initially agreed-upon cap amount for royalties is fully met. This arrangement ensures the consistent flow of concession revenues, irrespective of shifts in the company's ownership.
2026-02-23 12:36:36
ADC Therapeutics SA (ADCT) anticipates entering a substantial growth phase beginning in 2027, with potential annual revenue in the US market estimated between $600 million and $1 billion. This optimistic forecast is based on the commercialization of its core product pipeline and strategic market expansion within oncology treatment. The company's future financial performance is contingent on the successful execution of clinical development and market penetration strategies.
2026-02-23 12:14:49
ADC Therapeutics (NYSE: ADCT) has amended its royalty purchase agreement with HealthCare Royalty, reducing the change-of-control payment obligation to $150 million through December 31, 2027, and $200 million thereafter, down from a previous $750 million. In exchange, HealthCare Royalty received warrants to purchase approximately 9.8 million common shares at an exercise price of $3.81. This agreement provides ADC Therapeutics with greater strategic flexibility, particularly for its drug ZYNLONTA, which the company projects could achieve $600 million to $1 billion in annual US peak revenue.
2026-02-23 12:06:18
ADC Therapeutics (NYSE:ADCT) has granted warrants to Healthcare Royalty, allowing them to purchase approximately 9.8 million common shares at an exercise price of $3.81 per share. The biopharmaceutical company anticipates significant growth starting in 2027 and projects potential peak revenue in the United States to range from $600 million to $1 billion annually. This move is part of the company's financial strategy.
2026-02-23 12:06:18
Healthcare Royalty Partners has granted warrants to ADC Therapeutics SA, allowing them to purchase roughly 9.8 million ordinary shares. The exercise price for these warrants is set at $3.81 per share. This agreement could provide ADC Therapeutics SA with a capital injection and offers investors the right to acquire shares at a fixed future price.
